THERAPEUTIC AREA
saveOncology
Cancer and tumor biology across solid and hematologic malignancies.
also known as: cancer, tumor, onc
🐶 often sniffed alongside
top 8- tagBreast Cancer384 co-mentions · 38 sources
- tagNSCLC256 co-mentions · 47 sources
- tagPulmonology207 co-mentions · 51 sources
- tagProstate Cancer127 co-mentions · 20 sources
- tagColorectal Cancer123 co-mentions · 22 sources
- tagMelanoma92 co-mentions · 13 sources
- tagUrology73 co-mentions · 4 sources
- tagNephrology50 co-mentions · 4 sources
drugs
1,831
catalysts
148
news
9,659
companies
1,146
Top drugs
view all →Marketed
pembrolizumab
Merkel Cell Carcinoma
$MRK · 125 catalysts
Marketednivolumab
Colorectal Cancer
86 catalysts
Marketedgoserelin LA
Metrorrhagia (Abnormal Uterine Bleeding)
76 catalysts
Marketedtriptorelin pamoate ER
Central Precocious Puberty
64 catalysts
Marketedmethylprednisolone sodium succinate
Drug Hypersensitivity Reactions
48 catalysts
MarketedImatinib Mesylate Shilpa
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leuk…
46 catalysts
MarketedSpexotras
Low-Grade Glioma
$NVS · 43 catalysts
MarketedEfudex
Basal Cell Carcinoma (Basal Cell Epithelioma)
42 catalysts
🐶 Top companies
view all →Recent catalysts
view all →Apr 30, 2026
phase 2 completion
Nanfang Hospital of Southern Medical University — adebrelimab (Phase II Trial Completion)
adebrelimab
→
Apr 30, 2026
phase 2 completion
Cancer Institute and Hospital Chinese Academy of Medical Sciences — capecitabine (Phase II Trial Completion)
capecitabine
→
Apr 30, 2026
phase 2 completion
Hospital Of Dalian Medical University 1 — adebrelimab (Phase II Trial Completion)
adebrelimab
→
Apr 30, 2026
phase 2 completion
$RCUS23.83-2.81%
Arcus Biosciences Inc — atezolizumab (Phase II Trial Completion)
atezolizumab
→
Apr 30, 2026
phase 2 completion
Sun Pharmaceutical Industries Ltd — Absorica (Phase II Trial Completion)
ISOTRETINOIN
→
Apr 30, 2026
phase 2 completion
Chinese Academy of Medical Sciences and Peking Union Medical College — fuzuloparib (Phase II Trial Completion)
fuzuloparib
→
Apr 30, 2026
phase 2 completion
BioCanRx — ipilimumab (Phase II Trial Completion)
ipilimumab
→
Apr 30, 2026
phase 2 completion
National Cancer Institute US — ipilimumab (Phase II Trial Completion)
ipilimumab
→
Apr 30, 2026
phase 2 completion
Ohio State University Comprehensive Cancer Center — canakinumab (Phase II Trial Completion)
canakinumab
→
Apr 30, 2026
phase 2 completion
Wuhan Union Hospital — cadonilimab (Phase II Trial Completion)
cadonilimab
→
Recent news
view all →- Eli Lilly and the LA Dodgers: A tale of 2 dynastiesbiospace · 9h ago
- Merck barred from making subcutaneous Keytruda in 8 European countriesbiospace · 9h ago
- STAT+: AI for breast cancer risk prediction goes DTC, regulatory cloud over Utah sandbox, and AI psychosisstat · 12h ago
- STAT+: Roche goes beyond licensing in deal with Chinese biotechstat · 13h ago
- STAT+: Roche inks drug discovery deal with Chinese biotech, focused on molecular glue medicinesstat · 16h ago
- The Nobel boys club (again)stat · 16h ago
- Caribou to stop R&D work, start ‘substantial’ job cutsbiospace · 16h ago
- AI biotech Iambic aims for $135M IPO to push cancer drugs through clinicfiercebiotech · 19h ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that